Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of ...
Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Recursion Pharma is an AI-driven drug developer that boasts supercomputers designed to shorten drug development timelines and enhance successful outcomes. Many such companies have raised substantial ...
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback